Certain of Boston Scientific’s Cognis and Teligen implantable cardioverter defibrillators may fail prematurely due to battery issues, according to Australian and Chinese healthcare regulators.
Medical device maker Boston Scientific (NYSE:BSX) issued new warnings on its Cognis and Teligen implantable cardioverter defibrillators, advising physicians to watch out for premature battery depletion in older models.
The problematic implants are no longer available and haven’t been manufactured since December 2009, according to a physician letter, but the devices may be subject a component issue that may diminish device performance after as little as 2 years, eventually depleting the battery entirely. All cases reported thus far have been detected by the implants’ on-board diagnostic tools before the patients have experienced any symptoms, Boston Scientific said.
